Kiromic BioPharma, Inc. (KRBPQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Jul 15, 2026

Kiromic BioPharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Income
-23.77-23.77-19.94-31.11-25.31-9.81
Net Income
-4.63-4.63-13.82-35.08-25.81-19.91
Earnings Per Share
-3.17-3.17-12.59-64.42-67.82-132.58
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
1.141.143.20.6525.3510.15
Total Debt
14.5714.5715.549.410.450.47
Net Cash (Debt)
-13.43-13.43-12.34-8.7724.99.68
Net Cash Growth
----157.16%401.92%
Net Cash Per Share
-9.19-9.19-11.24-16.1065.4364.47

Cash Flow & CapEx

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-19.46-19.46-21.23-23.75-20.32-6.13
Capital Expenditures
-0.37-0.37-0.21-4.88-1.89-1.46
Free Cash Flow
-19.82-19.82-21.43-28.63-22.22-7.58
Free Cash Flow Growth
------